{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260616491572/en/CEL-SCI-Advances-Multikine%C2%AE-Immunotherapy-for-Head-and-Neck-Cancer-Through-Dual-U.S.-Registration-Study-and-Saudi-Market-Entry-Strategy", "message": "News view counter 801665 successfully enlarged"}